[go: up one dir, main page]

WO2006026556A2 - Preparations de formes posologiques orales bioadhesives a liberation regulee - Google Patents

Preparations de formes posologiques orales bioadhesives a liberation regulee Download PDF

Info

Publication number
WO2006026556A2
WO2006026556A2 PCT/US2005/030681 US2005030681W WO2006026556A2 WO 2006026556 A2 WO2006026556 A2 WO 2006026556A2 US 2005030681 W US2005030681 W US 2005030681W WO 2006026556 A2 WO2006026556 A2 WO 2006026556A2
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
bioadhesive
tablet
drug
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/030681
Other languages
English (en)
Other versions
WO2006026556A3 (fr
Inventor
Avinash Nangia
Jules S. Jacob
Peyman Moslemy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spherics Inc
Original Assignee
Spherics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/009,327 external-priority patent/US20050201974A1/en
Application filed by Spherics Inc filed Critical Spherics Inc
Priority to US11/661,540 priority Critical patent/US20080260824A1/en
Publication of WO2006026556A2 publication Critical patent/WO2006026556A2/fr
Publication of WO2006026556A3 publication Critical patent/WO2006026556A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • Bioadhesion results from a confluence of factors, including an intimate contact between the bioadhesive and the receptor tissue, penetration of the bioadhesive into the crevice of the tissue surface and/or mucus, and formation of mechanical, electrostatic, or chemical bonds. Bioadhesive properties of polymers are affected by both the nature of the polymer and by the nature of the surrounding media.
  • Figure 5 is a longitudinal section of a longitudinally compressed tablet containing drugs and excipients, and optionally permeation and/or dissolution enhancers, disposed in four monolithic layers.
  • the tablet is coated peripherally with a bioadhesive polymer, such as SpheromerTM II (anhydride oligomers blended with pharmaceutical polymers).
  • Figure 18 is a graph showing the in vitro release profile of Gabapentin Tablets, 500 mg in USP simulated gastric fluid conditions (Lots 411-108, 411-106, 411-029).
  • Figure 19 is a graph showing the in vitro release profile of Valacyclovir Tablets, 225 mg in USP simulated gastric fluid conditions (Lots 502-063, 502-065, 502-067).
  • Figure 21 is a graph showing the in vitro dissolution of Metformin HCl tablets, 500 mg under USP simulated gastric fluid conditions (Lot #412- 093).
  • Figure 22 is a graph showing the in vitro dissolution of Pioglitazone
  • Figure 34 is a longitudinal section of a longitudinally compressed tablet containing drugs and excipients, and optionally permeation and/or dissolution enhancers, disposed in three monolithic layers.
  • the tablet is coated peripherally with a bioadhesive polymer, such as SpheromerTM II (anhydride oligomers blended with pharmaceutical polymers). Drug is released from one end of the tablet in this design.
  • a bioadhesive polymer such as SpheromerTM II (anhydride oligomers blended with pharmaceutical polymers).
  • the present invention is an oral dosage form, such as a tablet, for oral delivery of a drug, comprising a compressed core including a drug to be delivered gastrointestinally, and a bioadhesive polymeric coating applied to at least one surface of the dosage form.
  • the coating preferably provides the dosage form with a fracture strength of at least 100 N/m 2 as measured on rat intestine, and the dosage form optimally has a gastrointestinal retention time of at least 4 hours in a fed beagle dog model during which the drug is released from the dosage form.
  • the dosage form optimally has a gastrointestinal retention time of at least 3 hours in a fasted beagle dog model during which the drug is released from the dosage form.
  • Bioadhesive materials described herein may be used in a wide variety of drug delivery and diagnostic applications. Bioadhesive materials may be formed into microparticles, such as microspheres or microcapsules, or may
  • the solid oral dosage form is a longitudinally compressed tablet 10 containing a single drug or more than one drug, excipients, and optionally permeation and/or dissolution enhancers, combined in a single monolithic layer 11.
  • the tablet is sealed peripherally with a layer of bioadhesive composition 12 leaving the upper and lower sides 13 A and 13B of the tablet available for drug release.
  • First-order and, more advantageously, zero-order release profiles are achievable with this tablet design. It is feasible to create different drug release rates by changing the composition of the core matrix.
  • the one or more drugs are delivered from a microporous/macroporous based osmotic delivery system.
  • Figure 14 illustrates the cross-section of a longitudinally compressed tablet 120 containing one or more drugs, excipients, and optionally permeation and/or dissolution enhancers, composed in a single core matrix 121.
  • the tablet is coated with a semi-permeable membrane 122 comprising a hydrophobic polymer and one or more hydrophilic pore formers or wicking agents.
  • the tablet is sealed peripherally with a matrix of bioadhesive composition 123 leaving the upper and lower sides 124 A and 124B of the tablet available for ⁇ water uptake and drug release.
  • the dosage formulation is targeted for delivery to the colonic region of the gastrointestinal tract. It is expected that the extended residence time in the colon with such bioadhesive formulations will result in improved efficacy due to high local drug concentrations and minimum systemic absorption. Targeted delivery to the colon can be achieved, for example, by coating the dosage formulation with a time- dependent and/or pH dependent polymer layer.
  • Longitudinally compressed core tablets containing the therapeutic agent and other components may be compressed onto a single or multilayer tableting machine equipped with deep fill or regular tooling.
  • the therapeutic agent either alone or in combination with a rate controlling polymer and other excipients is mixed by stirring, ball milling, roll milling or calendaring and pressed into a solid having dimensions conforming to an internal compartment defined by the extruded polymer cylinder.
  • the inner core system may be a pre-fabricated osmotic system that is inserted into the bioadhesive cylinder with orifices aligned along the open ends of the cylinder.
  • the water-insoluble metal compounds can be derived from a wide variety of metals, including, but not limited to, calcium, iron, copper, zinc, cadmium, zirconium and titanium.
  • the water insoluble metal compound preferably is a metal oxide or hydroxide. Water insoluble metal compounds of multivalent metals are preferred.
  • metal compounds which are incorporated into polymers to improve their bioadhesive properties can be metal compounds which are already approved by the FDA as either food or pharmaceutical additives, such as zinc oxide.
  • poly(alkylene glycols) such as polyethylene glycol); poly(alkylene oxides), such as poly(ethylene oxide); and poly(alkylene terephthalates), such as poly(ethylene terephthalate).
  • polyvinyl polymers can be used, which, as defined herein includes polyvinyl alcohols, polyvinyl ethers, polyvinyl esters and polyvinyl halides.
  • Exemplary polyvinyl polymers include poly(vinyl acetate), polyvinyl phenol and polyvinylpyrrolidone.
  • the longitudinally compressed tablets were first coated completely with a cellulose acetate (CA 398-10) plus PEG 400 based semi-permeable coating.
  • a passageway, 500 ⁇ m in size, on the cellulose acetate film was made on each side of the tablet by using a micro-drill.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un système d'administration de médicaments bioadhésifs selon lequel un noyaux contenant le médicament, soit seul, soit revêtu d'un système à membrane de régulation de la vitesse de libération, est enveloppé d'un revêtement bioadhésif, formant ainsi un système monolithique permettant une libération régulière du médicament. L'invention porte également sur des polymères à propriétés bioadhésives améliorées, et sur des méthodes d'amélioration de la bioadhérence de polymères.
PCT/US2005/030681 2003-12-09 2005-08-29 Preparations de formes posologiques orales bioadhesives a liberation regulee Ceased WO2006026556A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/661,540 US20080260824A1 (en) 2003-12-09 2005-08-29 Bioadhesive Rate-Controlled Oral Dosage Formulations

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US60499104P 2004-08-27 2004-08-27
US60520004P 2004-08-27 2004-08-27
US60499004P 2004-08-27 2004-08-27
US60519904P 2004-08-27 2004-08-27
US60520104P 2004-08-27 2004-08-27
US60519804P 2004-08-27 2004-08-27
US60/604,990 2004-08-27
US60/604,991 2004-08-27
US60/605,200 2004-08-27
US60/605,201 2004-08-27
US60/605,198 2004-08-27
US60/605,199 2004-08-27
US60790504P 2004-09-08 2004-09-08
US60/607,905 2004-09-08
US11/009,327 US20050201974A1 (en) 2003-12-09 2004-12-09 Bioadhesive polymers with catechol functionality
US11/009,327 2004-12-09
US63581204P 2004-12-13 2004-12-13
US60/635,812 2004-12-13
US65019105P 2005-02-04 2005-02-04
US65037505P 2005-02-04 2005-02-04
US60/650,191 2005-02-04
US60/650,375 2005-02-04
US67638305P 2005-04-29 2005-04-29
US60/676,383 2005-04-29

Publications (2)

Publication Number Publication Date
WO2006026556A2 true WO2006026556A2 (fr) 2006-03-09
WO2006026556A3 WO2006026556A3 (fr) 2006-08-10

Family

ID=35703707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030681 Ceased WO2006026556A2 (fr) 2003-12-09 2005-08-29 Preparations de formes posologiques orales bioadhesives a liberation regulee

Country Status (2)

Country Link
JP (1) JP2008516893A (fr)
WO (1) WO2006026556A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079404A3 (fr) * 2006-12-22 2009-03-19 Spherics Inc Compositions pharmaceutiques pour le traitement de la maladie de parkinson et de troubles apparentés
WO2007103286A3 (fr) * 2006-03-02 2009-07-02 Spherics Inc Formulations posologiques orales a liberation controlee
US9901640B2 (en) 2007-12-28 2018-02-27 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9968556B2 (en) 2010-04-01 2018-05-15 Theravida, Inc. Pharmaceutical formulations
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10328057B2 (en) 2016-01-20 2019-06-25 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP4206236A1 (fr) 2021-12-28 2023-07-05 Kao Corporation Composés, leurs synthèses et compositions comprenant les composés pour un dépôt amélioré de polymères sur des surfaces capillaires
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638240C (fr) * 2008-08-29 2010-02-02 Alexander Macgregor Methode de traitement des anomalies de la glycemie et des variations de la glycemie
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド ピロカルピンの医薬製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585585A (en) * 1984-03-07 1986-04-29 University Of Connecticut Research & Development Corporation Decapeptides produced from bioadhesive polyphenolic proteins
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
MXPA01005346A (es) * 1998-11-27 2003-03-27 Kanji Takada Una formulacion oral para suministro de farmaco gastrointestinal.
BR9903382A (pt) * 1999-08-04 2001-03-20 Fundacao Oswaldo Cruz Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos
US20030232088A1 (en) * 2002-06-14 2003-12-18 Kimberly-Clark Worldwide, Inc. Materials with both bioadhesive and biodegradable components
WO2004005421A1 (fr) * 2002-07-02 2004-01-15 Biopolymer Products Of Sweden Ab Utilisation d'une solution aqueuse acide d'une proteine polyphenolique bioadhesive comme adhesif ou revetement

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103286A3 (fr) * 2006-03-02 2009-07-02 Spherics Inc Formulations posologiques orales a liberation controlee
WO2008079404A3 (fr) * 2006-12-22 2009-03-19 Spherics Inc Compositions pharmaceutiques pour le traitement de la maladie de parkinson et de troubles apparentés
US9901640B2 (en) 2007-12-28 2018-02-27 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US10786457B2 (en) 2010-04-01 2020-09-29 Theravida, Inc. Pharmaceutical formulations
US9968556B2 (en) 2010-04-01 2018-05-15 Theravida, Inc. Pharmaceutical formulations
US10973769B2 (en) 2013-10-07 2021-04-13 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12178918B2 (en) 2013-10-07 2024-12-31 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12178919B2 (en) 2013-10-07 2024-12-31 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US10688058B2 (en) 2013-10-07 2020-06-23 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10292935B2 (en) 2013-10-07 2019-05-21 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12303605B2 (en) 2013-10-07 2025-05-20 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12274793B2 (en) 2013-10-07 2025-04-15 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US11357733B2 (en) 2013-10-07 2022-06-14 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11622941B2 (en) 2013-10-07 2023-04-11 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11666538B2 (en) 2013-10-07 2023-06-06 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12403099B2 (en) 2013-10-07 2025-09-02 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US12128141B1 (en) 2013-10-07 2024-10-29 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12064521B2 (en) 2013-10-07 2024-08-20 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10328057B2 (en) 2016-01-20 2019-06-25 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US11779569B2 (en) 2016-01-20 2023-10-10 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US11185533B2 (en) 2016-01-20 2021-11-30 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US10610519B2 (en) 2016-01-20 2020-04-07 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12109185B2 (en) 2020-12-22 2024-10-08 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12263149B2 (en) 2020-12-22 2025-04-01 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12263148B2 (en) 2020-12-22 2025-04-01 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12295931B2 (en) 2020-12-22 2025-05-13 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12303481B2 (en) 2020-12-22 2025-05-20 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12201596B2 (en) 2020-12-22 2025-01-21 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12303482B1 (en) 2020-12-22 2025-05-20 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12370163B2 (en) 2020-12-22 2025-07-29 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12458616B2 (en) 2020-12-22 2025-11-04 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12447139B2 (en) 2020-12-22 2025-10-21 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12453710B2 (en) 2020-12-22 2025-10-28 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
EP4206236A1 (fr) 2021-12-28 2023-07-05 Kao Corporation Composés, leurs synthèses et compositions comprenant les composés pour un dépôt amélioré de polymères sur des surfaces capillaires

Also Published As

Publication number Publication date
WO2006026556A3 (fr) 2006-08-10
JP2008516893A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
US20080260824A1 (en) Bioadhesive Rate-Controlled Oral Dosage Formulations
US20100226855A1 (en) Rate-Controlled Oral Dosage Formulations
US20080311191A1 (en) Multi-Layer Tablets and Bioadhesive Dosage Forms
US9931405B2 (en) Pharmaceutical compositions for gastrointestinal drug delivery
US9744137B2 (en) Topiramate compositions and methods of enhancing its bioavailability
AU2008282900B2 (en) Pulsatile gastric retentive dosage forms
JP6062465B2 (ja) カルビドパ／レボドパ胃内滞留性薬物供給
Dehghan et al. Gastroretentive drug delivery systems: A patent perspective
US20100316712A1 (en) Pharmaceutical compositions for treatment of parkinson&#39;s disease and related disorders
US20070281007A1 (en) Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
JP2003521507A (ja) ゼロ次薬物放出に接近するシェル−コア剤形
CA2412024A1 (fr) Compositions et forme posologique pour liberation gastrique retardee d&#39;alendronate et/ou d&#39;autres bis-phosphonates
WO2006026556A2 (fr) Preparations de formes posologiques orales bioadhesives a liberation regulee
US8491929B2 (en) Bioadhesive polymers
CA2635767A1 (fr) Comprime multicouche
AU2005285298A1 (en) Multi-layer tablets and bioadhesive dosage forms
US20120027855A1 (en) Pharmaceutical compositions for gastrointestinal drug delivery
US20170172928A1 (en) Pharmaceutical system for oral delivery of sensitive therapeutic substances
GB2443738A (en) A sustained release methotrexate composition and methods of use thereof
KR20210047779A (ko) 콜린알포세레이트를 함유하는 서방성 소형 경구 투여 제제
HK1158545B (en) Carbidopa/levodopa gastroretentive drug delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 11661540

Country of ref document: US